Relmada Therapeutics (Relmada Therapeutics) Ending Cash Position : $1.34 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Relmada Therapeutics Ending Cash Position?

Relmada Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 was $1.34 Mil.

Relmada Therapeutics's quarterly Ending Cash Position declined from Sep. 2023 ($6.70 Mil) to Dec. 2023 ($4.09 Mil) and declined from Dec. 2023 ($4.09 Mil) to Mar. 2024 ($1.34 Mil).

Relmada Therapeutics's annual Ending Cash Position declined from Dec. 2021 ($44.44 Mil) to Dec. 2022 ($5.40 Mil) and declined from Dec. 2022 ($5.40 Mil) to Dec. 2023 ($4.09 Mil).

Relmada Therapeutics Ending Cash Position Historical Data

The historical data trend for Relmada Therapeutics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relmada Therapeutics Ending Cash Position Chart

Relmada Therapeutics Annual Data

Trend

Aug13

Jun15

Jun16

Jun17

Jun18

Jun19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

9.22

2.50

44.44

5.40

4.09

Relmada Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Ending Cash Position	Get a 7-Day Free Trial															28.89	14.47	6.70	4.09	1.34

Relmada Therapeutics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Relmada Therapeutics's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	5.396	+	-1.304
	=	4.09

Relmada Therapeutics's Ending Cash Position for the quarter that ended in Mar. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	4.092	+	-2.757
	=	1.34

Relmada Therapeutics Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Relmada Therapeutics's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Relmada Therapeutics (Relmada Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relmada Therapeutics Inc (NAS:RLMD) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

4E2:Germany

Address

2222 Ponce de Leon Boulevard, Floor 3, Coral Gables, FL, USA, 33134

Website

https://www.relmada.com

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

Executives

Cedric O'gorman	officer: Chief Medical Officer	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Fabiana Fedeli	director	C/O RELMADA THERAPEUTICS, INC., 2222 PONCE DE LEON BLVD, 3RD FLOOR, CORAL GABLES FL 33134
Sergio Traversa	director, officer: Chief Executive Officer	138 CANTERBURY LN, BLUE BELL PA 19422
Paul Edward Kelly	director	300 EAST 56TH STREET, APT 19E, NEW YORK, NY 10022
Charles J Casamento	director	99 BELBROOK WAY, ATHERTON CA 94027
Maged Shenouda	director	305 WEST 18TH STREET, APT 4B, NEW YORK NY 10011
Thomas Wessel	officer: EVP, Head of R&D	15 SKYLINE DRIVE, HAWTHORNE NY 10532
Eric Thomas Schmidt	director	C/O ALLOGENE THERAPEUTICS, INC., 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
John Glasspool	director	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Chuck Ence	officer: Chief Financial Officer	3000 S. UNIVERSITY BLVD., DENVER CO 80210
Ottavio V. Vitolo	officer: Chief Medical Officer	71 WESTLAND AVENUE, NEWTON MA 02465
Shreeram Agharkar	director	P.O BOX 2042, PRINCETON NJ 08543
Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Lisa Nolan	officer: Chief Business Officer	36 ROCKLAND MILLS, ROCKLAND DE 19732
Eliseo Oreste Salinas	officer: President and CSO	7707 GATEWAY BLVD, NEWARK CA 94560